当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.

Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.

Abstract：

PURPOSE:The interindividual variability of vincristine pharmacokinetics is quite large, but the origins of this variability are not properly understood. The aim of this study was to develop a population pharmacokinetic model of vincristine in a paediatric population treated for solid tumour disease and evaluate the impact of different ABCB1, CYP3A4 and CYP3A5 polymorphisms on the different pharmacokinetic parameters. METHODS:We assessed vincristine pharmacokinetics in 26 children treated for various solid tumour diseases. Genotypes were determined by real-time PCR with a LightCycler™ and ABCB1 haplotypes calculated using the software program Phase 2.1. Vincristine plasma concentrations were determined by LC-MS/MS, and a population approach was performed on 184 samples by the NONMEM computer program. Demographic, therapeutic and genotypic covariables were evaluated on vincristine pharmacokinetic parameters. RESULTS:The frequency of CYP3A4*1A/*1A and *1A/*1B genotypes were 87.5 and 12.5%, respectively. CYP3A5*1/*3 and *3/*3 were observed in 20.8 and 79.2% of the patients, respectively. The three major haplotypes were (allelic frequencies) CGC (50%), CGT (14.6%) and TTT (23.2%). Vincristine pharmacokinetics was well described by a two-compartment model. Large interindividual and interoccasion variability were observed. The different polymorphisms studied did not improve the model prediction. CONCLUSIONS:CYP3A4, CYP3A5 and ABCB1 polymorphisms did not significantly affect in vivo vincristine pharmacokinetics. Our results demonstrate that vincristine pharmacokinetic variability cannot be explained by these genetic polymorphisms.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Guilhaumou R,Simon N,Quaranta S,Verschuur A,Lacarelle B,Andre N,Solas C

doi

10.1007/s00280-010-1541-4

subject

Has Abstract

pub_date

2011-11-01 00:00:00

pages

1191-8

issue

5

eissn

0344-5704

issn

1432-0843

journal_volume

68

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.

    abstract：BACKGROUND:Epidemiologic and preclinical data suggest isoflavones have anticancer activity in colorectal malignancy prevention and treatment. This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer. METHODS:Patients who had histol...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03886-3

    authors： Pintova S,Dharmupari S,Moshier E,Zubizarreta N,Ang C,Holcombe RF

    更新日期：2019-09-01 00:00:00

  • Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.

    abstract：PURPOSE:Normal white blood cell counts (WBC) are unknown in children with acute lymphoblastic leukemia (ALL). Accordingly, 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy is adjusted by a common WBC target of 1.5-3.0 × 109/L. Consequently, the absolute degree of myelosuppression is unknown for the ind...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3151-2

    authors： Nielsen SN,Grell K,Nersting J,Frandsen TL,Hjalgrim LL,Schmiegelow K

    更新日期：2016-11-01 00:00:00

  • Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

    abstract：PURPOSE:To evaluate the outcomes of intraperitoneal chemotherapy (IP) compared with those of intravenous chemotherapy (IV) in patients with advanced ovarian cancer after neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS). METHODS:Patients with advanced epithelial ov...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3591-y

    authors： Lee J,Curtin JP,Muggia FM,Pothuri B,Boyd LR,Blank SV

    更新日期：2018-07-01 00:00:00

  • Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice.

    abstract：:O-6-methylguanine (O6-mG), a guanine analog recently shown to be a potent inhibitor of alkylguanine-DNA alkyltransferase, has been found to potentiate the antitumor activity of nitrosoureas, in particular, carmustine (BCNU), in resistant cell lines (HT-29 mer+) and is targeted for development as a modulating agent wit...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686216

    authors： Avramis VI,Chan KK,Solorzano MM,Chen ZL

    更新日期：1993-01-01 00:00:00

  • Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.

    abstract：:In rabbits the IV kinetics of MTX (1.33, 4 and 12 mg/kg) could be described by a linear three-compartment model with a terminal half-life between 2.4 and 3.6 h. During 8 h 50% of the dose was excreted into urine in unchanged form and 15% as the metabolite 7-OH-MTX. These fractions remained constant with increasing dos...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257520

    authors： Iven H,Brasch H,Engster J

    更新日期：1985-01-01 00:00:00

  • Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.

    abstract：PURPOSE:Phosphatidylinositol (PtdIns) 3-kinase is an important mediator of many cellular functions. The study of PtdIns 3-kinase has been facilitated by the existence of the potent irreversible inhibitor of p110 PtdIns 3-kinase, wortmannin. The purpose of the study was to investigate the relationship between the cell g...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800051123

    authors： Lemke LE,Paine-Murrieta GD,Taylor CW,Powis G

    更新日期：1999-01-01 00:00:00

  • A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.

    abstract：PURPOSE:The dolastatins are a class of naturally occurring cytotoxic peptides which function by inhibiting microtubule assembly and tubulin polymerization. Cemadotin is a synthetic analogue of dolastatin 15 with potent antiproliferative and preclinical antitumor activity. This report describes a phase I study to evalua...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800000152

    authors： Supko JG,Lynch TJ,Clark JW,Fram R,Allen LF,Velagapudi R,Kufe DW,Eder JP Jr

    更新日期：2000-01-01 00:00:00

  • BCNU-induced quantitative and qualitative changes in hepatic cytochrome P-450 can be correlated with cholestasis.

    abstract：:Male Sprague-Dawley rats were given single i.p. injections of 1,3-bis(2-chloroethyl)-1-Nitrosourea (BCNU) to investigate changes in hepatic microsomal cytochrome P-450 content and metabolic activity. On day 14 after treatment (20 mg/kg), cytochrome P-450 content had decreased by approximately 25% and ethylmorphine N-d...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00684877

    authors： Stolzenbach JC,Larson RE

    更新日期：1990-01-01 00:00:00

  • Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.

    abstract：PURPOSE:Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine-chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. METHODS:In...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3446-y

    authors： Samaras P,Tusup M,Nguyen-Kim TDL,Seifert B,Bachmann H,von Moos R,Knuth A,Pascolo S

    更新日期：2017-11-01 00:00:00

  • A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene.

    abstract：PURPOSE AND METHODS:MS-209 is a newly synthesized quinoline compound used orally to overcome human P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). The multidrug resistance-associated protein (MRP) gene is thought to play an important role in MDR in lung cancer. To investigate whether MS-209 could also overcom...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050681

    authors： Narasaki F,Oka M,Fukuda M,Nakano R,Ikeda K,Takatani H,Terashi K,Soda H,Yano O,Nakamura T,Doyle LA,Tsuruo T,Kohno S

    更新日期：1997-01-01 00:00:00

  • Metformin and pancreatic cancer: Is there a role?

    abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA, with a 5-year survival rate of 6 %. Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-015-2948-8

    authors： De Souza A,Khawaja KI,Masud F,Saif MW

    更新日期：2016-02-01 00:00:00

  • Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

    abstract：:Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on m...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00253964

    authors： Zylicz Z,Wagener DJ,Fernandez del Moral P,van Rennes H,Wessels JM,Winograd B,van der Kleijn E,Vree TB,van Haelst U,van den Broek LA

    更新日期：1987-01-01 00:00:00

  • Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.

    abstract：BACKGROUND:Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in the clearance of several chemotherapeutic agents. In this st...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s00280-004-0946-3

    authors： Nygren P,Hande K,Petty KJ,Fedgchin M,van Dyck K,Majumdar A,Panebianco D,de Smet M,Ahmed T,Murphy MG,Gottesdiener KM,Cocquyt V,van Belle S

    更新日期：2005-06-01 00:00:00

  • Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer.

    abstract：:Copovithane is an uncharged, water-soluble, synthetic polymer with an average molecular weight of 5800 daltons. It demonstrates antitumor activity in vivo against a variety of tumors in animal models but is inactive in vitro. This agent has been found to have immunorestorative activity in man. In concert with its phas...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00273396

    authors： Rosenblum MG,Hortobagyi GN

    更新日期：1986-01-01 00:00:00

  • Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.

    abstract：PURPOSE:The aim of this study was to evaluate the efficacy and toxicity of cetuximab and pemetrexed as the second-line treatment for advanced esophageal cancer patients, who had undergone treatment with the standard cisplatin and 5-FU regimens. METHODS:A total of 29 patients accepted this treatment. Cetuximab was admi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-015-2854-0

    authors： Tian J,Shang M,Shi SB,Han Y,Xu J

    更新日期：2015-10-01 00:00:00

  • Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

    abstract：:The stability of solutions of the antitumour antimetabolites, vinca alkaloids, podophyllotoxins, interferons, steroids and platinum drugs as well as maytansine, asparaginase, amsacrine, flavone-8-acetic acid, mitoguazone, and N-phosphonoacetyl-L-aspartate (PALA) is reviewed. Much of the published work has been done wi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/BF00451642

    authors： Bosanquet AG

    更新日期：1989-01-01 00:00:00

  • Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.

    abstract：:A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050614

    authors： Looby M,Linke R,Weiss M

    更新日期：1997-01-01 00:00:00

  • Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.

    abstract：OBJECTIVE:To characterize the population pharmacokinetics of plitidepsin (Aplidin) in cancer patients. METHODS:A total of 283 patients (552 cycles) receiving intravenous plitidepsin as monotherapy at doses ranging from 0.13 to 8.0 mg/m(2) and given as 1- or 24-h infusions every week; 3- or 24-h infusion biweekly; or 1...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析

    doi：10.1007/s00280-008-0841-4

    authors： Nalda-Molina R,Valenzuela B,Ramon-Lopez A,Miguel-Lillo B,Soto-Matos A,Perez-Ruixo JJ

    更新日期：2009-06-01 00:00:00

  • Pharmacodynamic modeling of prolonged administration of etoposide.

    abstract：PURPOSE:A refined pharmacodynamic model for toxicity is necessary for successful adaptive control of the administration of an anticancer drug to avoid toxicity. We sought to establish a pharmacodynamic model of leukopenia in a 14-day administration of etoposide. METHODS:Pharmacokinetic data of 32 patients treated with...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050538

    authors： Minami H,Ratain MJ,Ando Y,Shimokata K

    更新日期：1996-01-01 00:00:00

  • Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.

    abstract：:The clinical formulation of leucovorin (5-CHO-FH4) is a mixture of diastereoisomers with markedly different pharmacologic properties. Comparatively little information is available concerning the cellular pharmacology of reduced folate stereoisomers, due largely to the difficulty in preparing sufficient quantities of t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF02897229

    authors： Lee PP,Schilsky RL

    更新日期：1990-01-01 00:00:00

  • NECTIN-4 increased the 5-FU resistance in colon cancer cells by inducing the PI3K-AKT cascade.

    abstract：PURPOSE:5-Fluorouracil is the most commonly used drug for the treatment of colon cancer, yet clinical resistance to this drug is frequently observed in patients making this drug ineffective. Thus, identification of gene responsible for 5-FU resistance is of utmost importance. METHODS:Cellular cytotoxicity and expressi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2794-8

    authors： Das D,Satapathy SR,Siddharth S,Nayak A,Kundu CN

    更新日期：2015-09-01 00:00:00

  • In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time.

    abstract：PURPOSE:The effect of an anticancer treatment on tumor cell proliferation in vitro can be described as a three-dimensional surface where the inhibitory effect is related to drug concentration and treatment time. The analysis of this kind of response surface could provide critical information: for example, it could indi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0688-7

    authors： Germani M,Magni P,De Nicolao G,Poggesi I,Marsiglio A,Ballinari D,Rocchetti M

    更新日期：2003-12-01 00:00:00

  • Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells.

    abstract：BACKGROUND AND PURPOSE:Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Triclosan, a common antibiotic, functions by inhibiting the enoyl-reductase enzymes of type II fatty ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-001-0399-x

    authors： Liu B,Wang Y,Fillgrove KL,Anderson VE

    更新日期：2002-03-01 00:00:00

  • A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.

    abstract：PURPOSE:The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP). METHODS:Previously unt...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2904-7

    authors： Shin DY,Choi YH,Lee HR,Na II,Yuh YJ,Kim BS,Chung IJ,Bae WK,Shim HJ,Song EK,Yang SH,Kang HJ

    更新日期：2016-01-01 00:00:00

  • Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.

    abstract：BACKGROUND:Addition of carboplatin (C) to trastuzumab (T) and paclitaxel (P) improves the efficacy in HER2+ metastatic breast cancer (MBC). The aim of this phase-II study was to evaluate the efficacy and safety of this combination given weekly (3x) followed by a week off. The primary endpoint was: objective response ra...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0709-7

    authors： Ruiz M,Salvador J,Bayo J,Lomas M,Moreno A,Valero M,Bernabé R,Vicente D,Jiménez J,Lopez-Ladrón A

    更新日期：2008-11-01 00:00:00

  • A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.

    abstract：PURPOSE:To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. METHODS:Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-009-1059-9

    authors： Oh DY,Cha Y,Choi IS,Yoon SY,Choi IK,Kim JH,Oh SC,Kim CD,Kim JS,Bang YJ,Kim YH

    更新日期：2010-02-01 00:00:00

  • Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

    abstract：PURPOSE:Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS:Patients received ramucir...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-018-3560-5

    authors： Smit EF,Garon EB,Reck M,Cappuzzo F,Bidoli P,Cohen RB,Gao L,O'Brien LM,Lee P,Zimmermann A,Ferry DR,Melemed AS,Pérol M

    更新日期：2018-07-01 00:00:00

  • Rescue of rats from large dose cyclophosphamide toxicity using protein A.

    abstract：:Cyclophosphamide (Cy) is widely used as an effective cytotoxic drug, but its use is limited because of its toxicity. In this report, we describe for the first time the ability of purified protein A (P) of Staphylococcus aureus to reduce Cy-induced toxicity in rats. Protein A-treated animals recover quickly from the to...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00552727

    authors： Ray PK,Dohadwala M,Bandyopadhyay SK,Canchanapan P,McLaughlin D

    更新日期：1985-01-01 00:00:00

  • Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

    abstract：PURPOSE:This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy. METHODS:Five cohorts of three patients received i.v. ascorbic acid administered at 1 g/min f...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2179-9

    authors： Stephenson CM,Levin RD,Spector T,Lis CG

    更新日期：2013-07-01 00:00:00

  • Population pharmacokinetic model of PI-88, a heparanase inhibitor.

    abstract：PURPOSE:The aim of this study was to investigate typical population pharmacokinetic (PK) parameters, potential covariates, and interindividual and residual variabilities of PI-88, a heparanase endoglycosidase enzyme inhibitor being developed for the treatment of cancer. METHODS:A population PK model of PI-88 was devel...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-1080-z

    authors： Hudachek SF,Eckhardt SG,Hicks B,Gustafson DL

    更新日期：2010-03-01 00:00:00